Microalbuminuria and its Prognostic Significance in Patients with Acute Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction by Ömer Doğan Alataş (12698849)

“…Therefore, we aimed to investigate the frequency and prognostic value of microalbuminuria in patients hospitalized for acute heart failure (AHF) with preserved ejection fraction (HFpEF), mid-range ejection fraction (HFmrEF), and reduced ejection fraction (HFrEF). …”

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction by Hannah A. Blair (6846307)

“…<br></p><p><br></p><p></p><p><b>Abstract </b>Dapagliflozin [Farxiga^® (USA); Forxiga^®(EU)], a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently approved in the USA and the EU for the treatment of adults with symptomatic heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI 58 trial, in which dapagliflozin 10 mg/day significantly reduced the risk of CV death or hospitalization for HF in patients with type 2 diabetes mellitus (T2DM) who had or were at risk for atherosclerotic CV disease. …”

Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction by Connie Kang (7248215)

“…<br> </p> <p><br></p> <p>Abstract</p> <p>Vericiguat (Verquvo^®) is the first oral soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of adults with symptomatic, chronic heart failure with reduced ejection fraction (HFrEF). In the phase III VICTORIA trial, vericiguat added to standard of care (SOC) was associated with a significantly lower risk of the primary composite endpoint of death from cardiovascular (CV) causes or first hospitalization from heart failure (HHF) than placebo added to SOC in adults with chronic HFrEF. …”

Cost-of-illness of heart failure with preserved and reduced ejection fraction in the Philippines by John Añonuevo (20494293)

“…</p> <p>The study utilized a bottom-up micro-costing approach to determine the economic burden of heart failure with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) across all NYHA classifications using a societal perspective. …”

Image 2_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 1_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Table 2_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.docx by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 4_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Table 1_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.docx by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 5_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Image 3_Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.jpeg by Yue Zhang (30585)

“…However, CV mortality was not significantly reduced in HFmrEF/HFpEF patients (HR: 0.92, 95% CI: 0.82–1.02, P = 0.13), but was reduced by 23% in HFrEF patients (HR: 0.77, 95% CI: 0.70–0.83, P < 0.00001). …”

Violin plots of diastolic HR and ejection fraction. by Alex J. Allphin (17102503)

Subjects:

Impact of Cardiorespiratory Fitness on the Obesity Paradox in Heart Failure with Reduced Ejection Fraction by Rita Ilhão Moreira (6299396)

“…<p></p><p>Abstract Background: Higher body mass index (BMI) has been associated with improved outcomes in heart failure with reduced ejection fraction. This finding has led to the concept of the obesity paradox. …”

Decrease of injuries. by Petr Fulin (8380320)

Subjects:

Auricular Vagal Neuromodulation and its Application in Patients with Heart Failure and Reduced Ejection Fraction by Sergio Menezes Couceiro (15475549)

Data_Sheet_1_The diagnostic value of peroxisome proliferator-activated receptor-γ coactivator-1α in identifying different chronic heart failure phenotypes.pdf by Shiwen Zhang (567333)

“…</p>Methods<p>A total of 172 participants were enrolled in the Affiliated Hospital of Xuzhou Medical University and were subsequently divided into four groups based on the European Society of Cardiology HF management guideline: the non-HF control (Control, N = 46), heart failure with reduced ejection fraction (HFrEF, N = 54), heart failure with mildly reduced ejection fraction (HFmrEF, N = 22), and heart failure with preserved ejection fraction (HFpEF, N = 50) groups. …”

Image_1_The diagnostic value of peroxisome proliferator-activated receptor-γ coactivator-1α in identifying different chronic heart failure phenotypes.pdf by Shiwen Zhang (567333)

“…</p>Methods<p>A total of 172 participants were enrolled in the Affiliated Hospital of Xuzhou Medical University and were subsequently divided into four groups based on the European Society of Cardiology HF management guideline: the non-HF control (Control, N = 46), heart failure with reduced ejection fraction (HFrEF, N = 54), heart failure with mildly reduced ejection fraction (HFmrEF, N = 22), and heart failure with preserved ejection fraction (HFpEF, N = 50) groups. …”

Decrease of admissions and lead diagnoses. by Petr Fulin (8380320)

Subjects:

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction by Qin-Fen Chen (20439211)

“…</p> <p>This retrospective study was conducted on patients diagnosed with heart failure with reduced ejection fraction (HFrEF) who underwent a second echocardiogram at least 6 months apart between January 2009 and February 2023. …”

Sensitivity analyses of seroprevalence with the largest sample size study omitted. by Yu Zhou (89766)